Diagnostic Pitfalls: Intramyocardial Lymphoma Metastasis Mimics Acute Coronary Syndrome in A Diffuse Large B Cell Lymphoma Patient – Case Report

Lilla Prenek
Kaposi Mor Megyei Korhaz  https://orcid.org/0000-0002-0933-9399

Klára Csupor
Kaposi Mor Megyei Korhaz

Péter Besztercán
Kaposi Mor Megyei Korhaz

Krisztina Boros
Kaposi Mor Megyei Korhaz

Erika Kardos
Kaposi Mor Megyei Korhaz

András Vorobcsuk
Kaposi Mor Megyei Korhaz

Miklós Egyed
Kaposi Mor Megyei Korhaz

Ádám Kellner
Kaposi Mor Megyei Korhaz

Péter Rajnics  rajnicsp@hotmail.com  https://orcid.org/0000-0003-3985-5826

Csaba Varga
Kaposi Mor Megyei Korhaz

Case report

Keywords: differential diagnosis, diffuse large B cell lymphoma, cardiac metastasis, coronary artery, acute coronary syndrome

DOI: https://doi.org/10.21203/rs.3.rs-96731/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Cardiac tumors are very uncommon compared to other cardiac diseases. Their clinical symptoms can vary from absent to nonspecific. The most common symptoms are arrhythmias, blood flow obstruction due to valvular dysfunction, shortness of breath, systemic embolization, accumulation of pericardial fluid. Hereby, we describe a very rare case of a diffuse large B cell lymphoma patient who presented with the symptoms and signs of acute coronary syndrome (ACS) but the patient’s complaints were caused by his intramyocardial lymphoma metastasis.

**Case presentation:** 48-year-old diffuse large B cell lymphoma patient was admitted to our emergency department with chest pain, effort dyspnea, and fever. The patient had normal blood pressure, blood oxygen saturation, sinus tachycardia, fever, crackles over the left lower lobe, novum incomplete right bundle branch block with Q waves and minor ST alterations, elevated C-reactive protein, high-sensitivity troponin-T and d-dimer levels. Chest X-ray revealed consolidation on the left side and enlarged heart. Bedside transthoracic echocardiography showed inferior akinesis with pericardial fluid. Coronary angiography showed no occlusion or significant stenosis. Chest computed tomography demonstrated the progression of his lymphoma in the myocardium. He was admitted to the Department of Hematology for immediate chemotherapy and he reached complete metabolic remission, followed by allogeneic hematopoietic stem cell transplantation. Unfortunately, about 9 months later, he developed bone marrow deficiency consequently severe sepsis, septic shock, and multiple organ failure what he did not survive.

**Conclusions:** Our case demonstrates a very rare manifestation of a heart metastasis. ACS is an unusual symptom of cardiac tumors. But our patient’s intramyocardial lymphoma in the right atrium and ventricle externally compressed the right coronary artery, causing the patient’s symptoms which imitated ACS. Fortunately, the quick diagnostics and immediate aggressive chemotherapy provided the patient’s remission and suitability to further treatment.

**Background**

Heart tumors are rare findings. The frequency of primary cardiac tumors ranges between 0.001-0.3% [1–3]. 75% of them are benign, 25% are malignant [4]. Atrial myxoma is the most frequent primary tumor in adults, and rhabdomyosarcoma is the most prevalent in children [5]. No malignant tumors are known which diffuse preferentially to the heart, some do involve the heart more often than others, for example melanoma and primary mediastinal tumors. The incidence of cardiac metastases reported in literature is highly variable, ranging from 2.3–18.3% in tumor patients. At autopsy they are more frequently found than the primary neoplasms of the heart [4–7]. The most common cardiac metastases are carcinomas, tissue sarcomas, melanomas, and lymphomas [8]. Most secondary cardiac tumors are clinically silent (90%) and are often diagnosed postmortem [9].

The incidence of emergency department visits among oncology patients ranges from 1%-12% up to 30% according to reviews [10–13]. Estimated frequency of hematological malignancies in male patients is...
around 7.5% [14]. Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) [15], representing approximately 24% of NHL patients [16]. These statistical data suggest that the occurrence of patients with hematological malignancies at the emergency department is around 0.5% or lower, which is in accordance with the statistics of our Department of Emergency.

Approximately 8–15% of all lymphoma patients have cardiac involvement [17, 18]. In the few existing cases in the medical literature, the heart seems to be more often involved in non-Hodgkin's lymphoma, whereas the pericardium is more often metastasized by Hodgkin's lymphoma [19]. These data show that the incidence of cardiac lymphoma in emergency departments is very uncommon.

Clinical manifestations of the heart tumors can be various, and nonspecific which often leads to their delayed diagnosis and management. The most commonly reported symptoms include valvular dysfunctions, arrhythmias, accumulation of pericardial fluid with or without tamponade, peripheral embolization with certain deficits. But some tumors do not cause any symptoms and remain only incidental findings [20, 21]. Secondary cardiac lymphoma patients also have a very poor outcome due to the high risk of sudden death. Most patients die before the start of therapy. For this reason, cardiac involvement should be diagnosed early [22].

**Case Presentation**

The 48-year-old male patient was diagnosed with germinal center (GC) subgroup of DLBCL developed from follicular lymphoma in 2017, after having a 6 months history of submandibular and inguinal lymphadenomegaly, and hepatomegaly.

He was in stage IV according to Ann Arbor classification at the time of diagnosis, and his international prognostic index was 3.

He received several regimes of chemotherapy but have not reached complete remission. Finally, a high dose methotrexate and rituximab treatment has resulted in significant morpho-metabolic regression in the lymphoma manifestations. Therefore homologous hematopoietic stem cell transplantation (HSCT) was planned. In July 2019 the patient underwent an unsuccessful attempt to collect enough stem cells for HSCT. Two weeks later he was admitted to our Department of Emergency with complaints of effort dyspnea, chest pain and fever. He received level 3 (urgent) on the triage scale (the Hungarian Emergency Triage System was adapted from the Canadian Triage Acuity Scale).

On physical examination the patient had normal blood pressure (138/80 mmHg) and blood oxygen saturation (96%), sinus tachycardia (133 beats per minute) and body temperature of 38.9 degrees of Celsius. On auscultation of the lungs mild crackles was heard over the left lower lobe. The patient’s electrocardiogram (ECG) revealed sinus tachycardia, and novum incomplete right bundle branch block with Q waves and minor ST elevations in leads II, III and aVF (Fig. 1).

From his laboratory findings at presentation elevated C-reactive protein (42.3 mg/l), high-sensitivity troponin-T (hsTnT) (432 pg/ml) and d-dimer (6376 ug/l) levels were notable (Table 1). After further
questioning it was also revealed that the patient forgot to administer his prophylactic low molecular weight heparin (LMWH) the day before his admission, which further supported the possibility of thromboembolism.

Chest X-ray (Fig. 2) showed consolidation or dystelectasis on the left side and significantly enlarged heart compared to the previous images. The enlarged heart raised the possibility of presence of pericardial fluid.

Because of the probability of pericardial effusion bed side transthoracic echocardiography (TTE) was performed which depicted inferior akinesis, reduced left ventricular function with 4–6 mm pericardial fluid and suggested coronarography following chest computed tomography (CT) to rule out pulmonary embolism.

Quick assessment of the chest CT images demonstrated no significant embolism.

Coronary angiography was immediately performed showed no occlusion or significant stenosis (Fig. 3).

In-depth analysis of the patient’s chest CT images (Fig. 4) revealed abnormal inhomogeneous hypodense tissue in the walls of the right ventricle and atrium considered as progression of his lymphoma. The size of this lesion was 50 × 22 mm in the lateral wall of the right ventricle and 84 × 59 mm in the wall of the right atrium, which externally compressed the right coronary artery. The CT images excluded embolism but supported the result of the chest X-ray demonstrating pneumonia.

The patient’s complaints were caused by the progression of his lymphoma therefore he was admitted to the Department of Hematology for further treatment. The patient received immediate therapy according to R-GemOx (gemcitabine-oxaliplatin plus rituximab) protocol complemented with venetoclax then he underwent polatuzumab-vedotin and rituximab, bendamustin treatment and his symptoms ameliorated, he reached complete metabolic remission. He went through allogeneic HSCT. Unfortunately, 9 months later, he was again admitted to our hospital with severe dyspnea and chest pain due to bone marrow deficiency. He developed severe sepsis, then septic shock with multiple organ failure what he did not survive.

Discussion And Conclusions

The WHO classification of tumors of hematopoietic and lymphoid tissues divides DLBCL into several subtypes including GC B cell subgroup [23]. DLBCL is the most frequent lymphoma subtype, accounts for about one third of the newly diagnosed lymphoma cases worldwide [24]. The different subtypes show significant differences in pathogenesis and clinical manifestation and most importantly are treated differently from classical DLBCL. Therefore the exact origin of the malignant cell and its molecular background must be determined [23].

Cardiac metastases are rare, and usually develop clinically silent or have nonspecific symptoms. Therefore, they are difficult to diagnose and are frequently detected postmortem during an autopsy. In
patients with lymphoma the cardiac involvement is seen in 8–15% of the cases and most of them are of B cell origin [25]. Clinical manifestations are highly variable, including heart failure, arrhythmias, valvular disease, and cardiac tamponade [26]. Due to the varying clinical presentations of cardiac lymphoma metastases the detection is often incidental.

If the signs and symptoms of cardiac disease are present non-invasive imaging is key in prompt diagnosis [27, 28]. Chest radiography may indicate cardiomegaly caused by pericardial effusion, abnormal shape of the heart, or lung congestion [8]. Echocardiography is the most frequently used non-invasive imaging technique to assess the heart. TTE is useful in the initial evaluation of suspected cardiac disease, but sometimes transesophageal echocardiography is required for a more accurate assessment [29]. The diagnostic accuracy of echocardiography is around 80% in the evaluation of suspected cardiac tumors [30]. CT and magnetic resonance imaging provide additional detail of the surrounding extracardiac structures, including the lungs, mediastinum and pleura [31]. Positron emission tomography (PET)/CT may provide additional utility and improved accuracy in earlier detection of metastases involving the heart [32].

There is no standard treatment of cardiac metastases in lymphomas. The therapy of choice is mostly influenced by the location of the metastasis and the patient’s condition. The individualized treatment often means interdisciplinary cooperation of oncologists, radiotherapists and surgeons [3].

In our case the patient showed nonspecific symptoms, such as effort dyspnea, chest discomfort, even fever. His physical status, laboratory and ECG findings supported the presence of more common conditions. Fever and crackles found on physical examination, the two-week-old history of chest pain and the fact that the patient is actively treated with chemotherapy due to hematological malignancy suggested pneumonia in the background. His ECG finding with the previously non-described incomplete right bundle branch block strengthen the possibility of pneumonia but also raised the possibility of pulmonary embolism and acute coronary syndrome. Therefore, the patient’s blood was tested for infection, d-dimer, and high-sensitivity troponin-T and chest X-ray was performed. The first result confirmed pneumonia but the high d-dimer and hsTnT indicated the need of further investigation. High d-dimer suggested the possibility of pulmonary embolism. He even admitted forgetting to administer his prophylactic LMWH the day before his admission.

Pulmonary embolism can be accompanied by elevated hsTnT level [33] and vice versa elevated d-dimer level may occur in ischemic heart disease [34]. The GRACE score of the patient was 101 points, his hsTnT level was high enough to fulfill a high-risk criterium for acute coronary syndrome. His Well’s score was 5.5 suggesting a moderate risk for pulmonary embolism [34]. The possibility of both conditions, myocardial infarction and pulmonary embolism, was present consequently, thus one of them must have to be excluded. We performed TTE to detect the presence of right ventricular dilatation as a sign for acute pulmonary embolism or myocardial hypo-akinesis due to myocardial infarction. TTE showed inferior akinesis, still, the possibility of pulmonary embolism was not clearly excluded. According to the guideline of the European Society of Cardiology if the patient’s initial evaluation suggests pulmonary embolism CT
angiography is recommended before coronary angiography [33]. Chest CT can effectively exclude not only pulmonary embolism, but other causes of chest pain as well which, if untreated, can be associated with high mortality. Quick assessment of the chest CT showed no embolism. Thus the coronary angiography was immediately performed in correlation with the early invasive strategy [33], but no occlusion or significant stenosis was found in the coronary arteries. While the coronary angiography was done the fine analysis of the chest CT revealed the intramyocardial progression of the patient’s lymphoma.

His fever was caused by concomitant consolidation in the left lower lobe and was successfully cured by imipenem-cilastatin combination. High d-dimer was most likely the consequence of the patient’s primary disease, the lymphoma, and not the result of thromboembolism as we first predicted [35]. The high troponin-T level was observed because the lymphoma damaged the heart tissue leading to the release of this protein [33].

Most of his findings suggested thromboembolism, myocardial infarction or pneumonia in the background of his complaints rather than the presence of intramyocardial lymphoma.

This case illustrate that rarely healthy coronary arteries can cause inappropriate blood supply to the heart muscle if they are externally compressed by such a rare finding as an intramyocardial malignant lymphoid tissue. The patient was fortunate because of the early diagnosis (Table 2) and successful treatment of his cardiac lymphoma metastasis provided him almost a year survival.

To conclude, primary and secondary cardiac tumors are uncommon diseases. Their clinical symptoms are variable, acute coronary syndrome is among the rarest. Our patient’s case is unique because he presented the symptoms of more common conditions, which affect large populations, such as pulmonary embolism, pneumonia, ACS, aortic dissection, pneumothorax, rupture of the esophagus or pericarditis. The early diagnosis and management of these diseases in emergency department settings is crucial for the survival of the patient. But the patient's findings revealed cardiac lymphoma metastasis which externally compressed the right coronary artery, leading to symptoms mimicking ACS. Fortunately, the quick diagnosis and efficient cooperation with cardiologists, radiologists and hematologists permitted the instant adequate therapy to the patient.

**List Of Abbreviations**

ACS acute coronary syndrome

CT computed tomography

DLBCL diffuse large B cell lymphoma

ECG electrocardiogram

GC germinal center
Declarations

Ethics approval and consent to participate

Ethics committee approval was obtained from the Ethics and Research Committee of the Somogy County Kaposi Mór Teaching Hospital (Reference Number: IG/00451-000/2020)

Consent for publication

Written informed consent was obtained from the patient's relative for publication of this case report and accompanying images

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request

Competing interests

The authors declare that they have no competing interests

Authors’ contribution

All authors were involved in delivery of the investigation. They all read and approved the final manuscript. PL analyzed the patient's data and relevant literature and prepared the manuscript, KCS, PB, ME, ÁK participated in the treatment of the patient, EK performed, analyzed the radiological scans and provided CT images, AV performed coronary angiography and provided angiographic images, LP, CSV conceptualized the case report, KB, CSV supervised the manuscript

Funding

Not applicable

Acknowledgements

Not applicable
References

1. Centofanti P, Di Rosa E, Deorsola L, Actis Dato GM, Patanè F, La Torre M, et al. Primary cardiac tumors: Early and late results of surgical treatment in 91 patients. In: Annals of Thoracic Surgery. Elsevier Inc.; 1999. p. 1236–41.

2. Patel J, Sheppard MN. Pathological study of primary cardiac and pericardial tumours in a specialist UK Centre: Surgical and autopsy series. Cardiovasc Pathol. 2010;19:343–52. doi:10.1016/j.carpath.2009.07.005.

3. Hoffmeier A, Sindermann JR, Scheld HH, Martens S. Herztumoren - Diagnostik und chirurgische therapie. Deutsches Arzteblatt International. 2014;111:205–11.

4. Amano J, Nakayama J, Yoshimura Y, Ikeda U. Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. General Thoracic and Cardiovascular Surgery. 2013;61:435–47.

5. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996;77:107.

6. Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastases. Journal of Clinical Pathology. 2007;60:27–34.

7. Al-Mamgani A, Baartman L, Baaijens M, De Pree I, Incrocci L, Levendag PC. Cardiac metastases. International Journal of Clinical Oncology. 2008;13:369–72.

8. Strecker T, Rösch J, Weyand M, Agaimy A. Primary and metastatic cardiac tumors: Imaging characteristics, surgical treatment, and histopathological spectrum: A 10-year-experience at a German heart center. Cardiovasc Pathol. 2012;21:436–43.

9. Burazor I, Aviel-Ronen S, Imazio M, Goitein O, Perelman M, Shelestovich N, et al. Metastatic cardiac tumors: From clinical presentation through diagnosis to treatment. BMC Cancer. 2018;18.

10. Lash RS, Bell JF, Reed SC, Poghosyan H, Rodgers J, Kim KK, et al. A systematic review of emergency department use among cancer patients. Cancer Nursing. 2017;40:135–44.

11. Mayer DK, Travers D, Wyss A, Leak A, Waller A. Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol. 2011;29:2683–8.

12. Lash RS, Bell JF, Bold RJ, Joseph JG, Cress RD, Wun T, et al. Emergency department use by recently diagnosed cancer patients in California. J Community Support Oncol. 2017;15:95–102.

13. Rivera DR, Gallicchio L, Brown J, Liu B, Kyriacou DN, Shelburne N. Trends in adult cancer-related emergency department utilization: An analysis of data from the nationwide emergency department sample. JAMA Oncol. 2017;3:e172450–e172450.

14. Roman E, Smith AG. Epidemiology of lymphomas. Histopathology. 2011;58:4–14.

15. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130:410–23.

16. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94:604–16. doi:10.1002/ajh.25460.
17. Silvestri F, Bussani R, Pavletic N, Mannone T. Metastases of the heart and pericardium. G Ital Cardiol. 1997;27:1252–5.

18. Chinen K, Izumo T. Cardiac involvement by malignant lymphoma: A clinicopathologic study of 25 autopsy cases based on the WHO classification. Ann Hematol. 2005;84:498–505. doi:10.1007/s00277-005-1009-5.

19. Moore JA, DeRan BP, Minor R, Julie A, Fraker TD. Transesophageal echocardiographic evaluation of intracardiac lymphoma. Am Heart J. 1992;124:514–6. doi:10.1016/0002-8703(92)90623-4.

20. Bossert T. Surgical experience with 77 primary cardiac tumors. Interact Cardiovasc Thorac Surg. 2005;4:311–5.

21. Schrepfer S, Deuse T, Detter C, Treede H, Koops A, Boehm DH, et al. Successful resection of a symptomatic right ventricular lipoma. Ann Thorac Surg. 2003;76:1305–7.

22. Tanaka T, Sato T, Akifuji Y, Sakamoto M, Shio H, Ueki J, et al. Aggressive non-Hodgkin’s lymphoma with massive involvement of the right ventricle. Intern Med. 1996;35:826–30.

23. Choi SM, O’Malley DP. Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. Annals of Diagnostic Pathology. 2018;37:67–74.

24. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004-2014: Sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112:1575–84.

25. Fujita Y, Ikekuchi M, Tarui S, Irie H. Successful combined treatment of primary cardiac malignant lymphoma with urgent cardiac operation and chemotherapy. Circ J. 2009;73:967–9.

26. Kim JK, Sindhu K, Bakst RL. Cardiac Metastasis in a Patient with Head and Neck Cancer: A Case Report and Review of the Literature. Case Rep Otolaryngol. 2019;2019.

27. Grebenc ML, Rosado De Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: Radiologic-pathologic correlation. Radiographics. 2000;20:1073–103.

28. Jellis C, Hunter A, Sutton R. Multimodal imaging of an atrial myxoma. Cardiovasc Pathol. 2009;18:379–80.

29. Alam M, Rosman HS, Grullon C. Transesophageal Echocardiography in Evaluation of Atrial Masses. Angiology. 1995;46:123–8.

30. Nomoto N, Tani T, Konda T, Kim K, Kitai T, Ota M, et al. Primary and metastatic cardiac tumors: Echocardiographic diagnosis, treatment and prognosis in a 15-years single center study. J Cardiothorac Surg. 2017;12.

31. Chiles C, Woodard PK, Gutierrez FR, Link KM. Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics. 2001;21:439–49.

32. Mittal B, Manohar K, Kashyap R, Bhattacharya A, Varma S, Agrawal K. FDG PET/CT in Detection of Metastatic Involvement of Heart and Treatment Monitoring in Non-Hodgkin’s Lymphoma. World J Nucl Med. 2012;11:33.
33. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of . European Heart Journal. 2016.

34. Konstantinides S V., Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2019;54:1901647.

35. Kabrhel C, Mark Courtney D, Camargo CA, Plewa MC, Nordenholz KE, Moore CL, et al. Factors Associated With Positive D-dimer Results in Patients Evaluated for Pulmonary Embolism. Acad Emerg Med. 2010;17:589–97. doi:10.1111/j.1553-2712.2010.00765.x.

Tables

**Table 1 Laboratory parameters of the patient**
| Laboratory parameter                  | Reference range | day 1 | day 3 | day 4 | day 9 | day 11 |
|--------------------------------------|----------------|-------|-------|-------|-------|--------|
| white blood cells (G/L)              | 4.5-10.1        | 5.25  | 4.48  | 3.88  | 1.21  |
| red blood cells (T/L)                | 4.1-5.1         | 2.51  | 2.45  | 2.29  | 2.88  |
| hemoglobin (g/L)                     | 140-175         | 87    | 81    | 76    | 95    |
| hematocrite (%)                      | 40-52           | 25.8  |       |       |       |
| platelet count (G/L)                 | 100-450         | 105   |       |       |       |
| INR                                  | 0.8-1.2         | 1.06  |       |       |       |
| D-dimer (µg/L)                       | 0-500           | 6376  | 3514  |       |       |
| CRP (mg/L)                           | 0-5             | 42.3  | 89.7  | 12.6  |       |
| glucose (mmol/L)                     | 3.3-5.5         | 5.1   |       |       |       |
| sodium (mmol/L)                      | 132-146         | 136   |       |       |       |
| potassium (mmol/L)                   | 3.3-5.4         | 4.07  |       |       |       |
| AST (U/L)                            | 0-45            | 23    |       |       |       |
| ALT (U/L)                            | 0-50            | 12    |       |       |       |
| GGT (U/L)                            | 8-60            | 44    |       |       |       |
| ALP (U/L)                            | 40-130          |       |       |       |       |
| Amilase (U/L)                        | 28-100          |       |       |       |       |
| CK (U/L)                             | 20-200          | 179   |       |       |       |
| LDH (U/L)                            | 240-280         | 808   | 712   | 420   |       |
| se/bilirubin (µmol/L)                | 0-20            | 12    |       |       |       |
| GFR (ml/min)                         | 90-1000         | 66    | 72    |       |       |
| creatinine (µmol/L)                  | 62-106          | 114   | 105   | 91    |       |
| urea (mmol/L)                        | 0.00-11.9       | 4.4   |       |       |       |
| hsTnT (pg/ml)                        | 0-14            | 432.1 | 329.6 | 103   |       |

Laboratory parameters of the patient at the Department of Emergency (Day 1) and the Department of Hematology (Day 2-11) (numbers in bold indicate alterations from the normal value)

Table 2 Time points of diagnostic procedures and the total time until the final diagnosis of the patient
| time (min) | Test                                      |
|-----------|-------------------------------------------|
| 0         | physical examination                      |
| 32        | chest X-ray                               |
| 47        | laboratory test                           |
| 250       | echocardiography                          |
| 311       | chest computed tomography                 |
| 336       | coronarography                            |
| 386       | Dept. of Hematology                       |
| **Total:**| **6h 26min**                              |